New article in Health Reform Observer

HRO logo

Evaluating the Cost-effectiveness of Pharmaceuticals in Canada

This article describes the adoption of the first Canadian Guidelines for Economic Evaluation of Pharmaceuticals in 1994, and creation of the Common Drug Review in 2003. It finds that although the CDR’s design and implementation respond to some of the shortcomings of the Canadian guidelines, there are still important unresolved tensions between harmonization and transparency in drug assessment, and new challenges regarding pharmaceutical pricing and use of evidence. The way these tensions are resolved has important implications for broader attempts to reform public drug coverage in Canada